{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:25:23Z","timestamp":1787279123590,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Synapse loss is the best correlate of cognitive decline in neurodegenerative diseases (NDDs). In Alzheimer\u2019s disease complement dysregulation, triggered by amyloid-\u03b2 accumulation, plays a major role in synapse loss, but its contribution in other NDDs where amyloid is absent, most notably tauopathies, is elusive. Aggregation of tau is a prominent co-pathology in many NDDs and is characteristic of classical tauopathies in which amyloid pathology is lacking. Here we explore the effect of tau accumulation on complement dysregulation and its contribution to neuronal damage and synapse loss in a mouse tauopathy model harbouring the familial P301S tau mutation and post-mortem brain samples from human tauopathies. Complement gene and protein expression were analysed in P301S mice at 2, 4 and 6 M of age. Complement dysregulation was evident from qPCR analysis showing increased classical pathway (C4, C2), and complement receptor (C3ar1, Cd11b, Cd11c) gene expression in P301S mice compared to wildtype (WT). C1q protein levels were markedly increased in brain homogenates from P301S mice compared to WT, accompanied by C1q deposition on tau aggregates. Synapse loss was evident for both excitatory and inhibitory synapses and was accompanied by an increased percentage of C1q positive excitatory synapses, unaffected by proximity to tau aggregates. The classic pathway regulator CSMD1 was present on synapses and decreased on C1q positive synapses in P301S mice, implying a loss of protection from complement attack. Observations in human tauopathy brains demonstrated decreased CSMD1-labelled excitatory synapses, consistent with findings in P301S mice. These findings demonstrate that complement dysregulation occurs in areas of tau pathology and may contribute to synapse loss in tauopathies.<\/jats:p>","DOI":"10.1186\/s40478-026-02347-2","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:54:39Z","timestamp":1781110479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dysregulation of complement at the synapse in P301S mice and human tauopathies"],"prefix":"10.1186","volume":"14","author":[{"given":"Jacqui","family":"Nimmo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Daskoulidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Van Pottelberge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"De Muynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Paul","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"6286","key":"2347_CR1","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S et al (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Sci (New York NY) 352(6286):712\u2013716. https:\/\/doi.org\/10.1126\/science.aad8373","journal-title":"Sci (New York NY)"},{"key":"2347_CR2","doi-asserted-by":"publisher","unstructured":"Dejanovic B, Wu T, Tsai M, Graykowski D, Gandham V, Rose C et al (2022) Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer\u2019s disease mouse models. Nat Aging 2(9). https:\/\/doi.org\/10.1038\/s43587-022-00281-1","DOI":"10.1038\/s43587-022-00281-1"},{"key":"2347_CR3","doi-asserted-by":"publisher","unstructured":"Nimmo J, Byrne R, Daskoulidou N, Watkins L, Carpanini S, Zelek W et al (2024) The complement system in neurodegenerative diseases. Clin Sci (Lond Engl 1979) 138(6). https:\/\/doi.org\/10.1042\/CS20230513","DOI":"10.1042\/CS20230513"},{"key":"2347_CR4","doi-asserted-by":"publisher","unstructured":"Carpanini S, Torvell M, Bevan R, Byrne R, Daskoulidou N, Saito T et al (2022) Terminal complement pathway activation drives synaptic loss in Alzheimer\u2019s disease models. Acta Neuropathol Commun 10(1). https:\/\/doi.org\/10.1186\/s40478-022-01404-w","DOI":"10.1186\/s40478-022-01404-w"},{"issue":"6","key":"2347_CR5","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N et al (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131(6):1164\u20131178. https:\/\/doi.org\/10.1016\/j.cell.2007.10.036","journal-title":"Cell"},{"key":"2347_CR6","doi-asserted-by":"publisher","unstructured":"Shi Q, Chowdhury S, Ma R, Le K, Hong S, Caldarone B et al (2017) Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci Transl Med 9(392). https:\/\/doi.org\/10.1126\/scitranslmed.aaf6295","DOI":"10.1126\/scitranslmed.aaf6295"},{"issue":"1","key":"2347_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00281-017-0662-9","volume":"40","author":"BP Morgan","year":"2018","unstructured":"Morgan BP (2018) Complement in the pathogenesis of Alzheimer\u2019s disease. Semin Immunopathol 40(1):113\u2013124. https:\/\/doi.org\/10.1007\/s00281-017-0662-9","journal-title":"Semin Immunopathol"},{"issue":"6","key":"2347_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/bf00192116","volume":"426","author":"R Veerhuis","year":"1995","unstructured":"Veerhuis R, van der Valk P, Janssen I, Zhan SS, Van Nostrand WE, Eikelenboom P (1995) Complement activation in amyloid plaques in Alzheimer\u2019s disease brains does not proceed further than C3. Virchows Arch Int J Pathol 426(6):603\u2013610. https:\/\/doi.org\/10.1007\/bf00192116","journal-title":"Virchows Arch Int J Pathol"},{"issue":"1\u20132","key":"2347_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0006-8993(94)91640-3","volume":"645","author":"S Itagaki","year":"1994","unstructured":"Itagaki S, Akiyama H, Saito H, McGeer PL (1994) Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer\u2019s disease. Brain Res 645(1\u20132):78\u201384. https:\/\/doi.org\/10.1016\/0006-8993(94)91640-3","journal-title":"Brain Res"},{"key":"2347_CR10","doi-asserted-by":"publisher","unstructured":"Nimmo J, Keat S, De ML, Morgan B (2025) Complement dysregulation in human tauopathies. Brain Pathol (Zurich, Switzerland). https:\/\/doi.org\/10.1111\/bpa.70017","DOI":"10.1111\/bpa.70017"},{"issue":"1","key":"2347_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-023-00601-y","volume":"18","author":"K Wenger","year":"2023","unstructured":"Wenger K, Viode A, Schlaffner CN, van Zalm P, Cheng L, Dellovade T et al (2023) Common mouse models of tauopathy reflect early but not late human disease. Mol Neurodegen 18(1):1\u201315. https:\/\/doi.org\/10.1186\/s13024-023-00601-y","journal-title":"Mol Neurodegen"},{"issue":"21","key":"2347_CR12","doi-asserted-by":"publisher","first-page":"9340","DOI":"10.1523\/JNEUROSCI.22-21-09340.2002","volume":"22","author":"B Allen","year":"2002","unstructured":"Allen B, Ingram E, Takao M, Smith M, Jakes R, Virdee K et al (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22(21):9340\u20139351. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-21-09340.2002","journal-title":"J Neurosci"},{"key":"2347_CR13","doi-asserted-by":"publisher","unstructured":"Wu T, Dejanovic B, Gandham V, Gogineni A, Edmonds R, Schauer S et al (2019) Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep 28(8). https:\/\/doi.org\/10.1016\/j.celrep.2019.07.060","DOI":"10.1016\/j.celrep.2019.07.060"},{"key":"2347_CR14","doi-asserted-by":"publisher","unstructured":"Dejanovic B, Huntley M, De Mazi\u00e8re A, Meilandt W, Wu T, Srinivasan K et al (2018) Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron 100(6). https:\/\/doi.org\/10.1016\/j.neuron.2018.10.014","DOI":"10.1016\/j.neuron.2018.10.014"},{"key":"2347_CR15","doi-asserted-by":"publisher","unstructured":"Byrne R, Torvell M, Daskoulidou N, Fathalla D, Kokkali E, Carpanini S et al (2021) Novel monoclonal antibodies against mouse C1q: characterisation and development of a quantitative ELISA for mouse C1q. Mol Neurobiol 58(9). https:\/\/doi.org\/10.1007\/s12035-021-02419-5","DOI":"10.1007\/s12035-021-02419-5"},{"key":"2347_CR16","doi-asserted-by":"publisher","unstructured":"Zelek W, Stott M, Walters D, Harris C, Morgan B (2018) Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155(3). https:\/\/doi.org\/10.1111\/imm.12982","DOI":"10.1111\/imm.12982"},{"key":"2347_CR17","doi-asserted-by":"publisher","unstructured":"Byrne R, Nimmo J, Torvell M, Carpanini S, Daskoulidou N, Hughes T et al (2025) The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain Behav Immun. 127. https:\/\/doi.org\/10.1016\/j.bbi.2025.03.026","DOI":"10.1016\/j.bbi.2025.03.026"},{"issue":"1","key":"2347_CR18","doi-asserted-by":"publisher","first-page":"11132","DOI":"10.1038\/s41467-025-66048-5","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Watson B, Rattan A, Lee T, Chawla S, Geistlinger L et al (2025) A spatial atlas of the complement system uncovers unique expression patterns in postnatal brain development in mice. Nat Commun 16(1):11132. https:\/\/doi.org\/10.1038\/s41467-025-66048-5","journal-title":"Nat Commun"},{"issue":"7","key":"2347_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/nan.12233","volume":"41","author":"J van Eersel","year":"2015","unstructured":"van Eersel J, Stevens CH, Przybyla M, Gladbach A, Stefanoska K, Chan CK et al (2015) Early-onset axonal pathology in a novel P301S-Tau transgenic mouse model of frontotemporal lobar degeneration. Neuropathol Appl Neurobiol 41(7):906\u2013925. https:\/\/doi.org\/10.1111\/nan.12233","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2347_CR20","doi-asserted-by":"publisher","unstructured":"Kraus D, Elliott G, Chute H, Horan T, Pfenninger K, Sanford S et al (1950) CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues. Journal of immunology (Baltimore, Md: 2006;176(7). https:\/\/doi.org\/10.4049\/jimmunol.176.7.4419","DOI":"10.4049\/jimmunol.176.7.4419"},{"key":"2347_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.bbi.2024.03.041","volume":"119","author":"M Baum","year":"2024","unstructured":"Baum M, Wilton D, Fox R, Carey A, Hsu Y, Hu R et al (2024) CSMD1 regulates brain complement activity and circuit development. Brain Behav Immun 119:317\u2013332. https:\/\/doi.org\/10.1016\/j.bbi.2024.03.041","journal-title":"Brain Behav Immun"},{"key":"2347_CR22","doi-asserted-by":"publisher","unstructured":"Jie W, Qi H, Xing C, Zhiwen Y, Kun H, Xiaoxie M et al (2025) Prediction of longitudinal synaptic loss in Alzheimer\u2019s disease using tau PET and plasma biomarkers. Alzheimer\u2019s Dement 21(5). https:\/\/doi.org\/10.1002\/alz.70333","DOI":"10.1002\/alz.70333"},{"key":"2347_CR23","doi-asserted-by":"publisher","unstructured":"Yao Y, Chang Y, Li S, Zhu J, Wu Y, Jiang X et al (2023) Complement C3a receptor antagonist alleviates tau pathology and ameliorates cognitive deficits in P301S mice. Brain Res Bull 200. https:\/\/doi.org\/10.1016\/j.brainresbull.2023.110685","DOI":"10.1016\/j.brainresbull.2023.110685"},{"key":"2347_CR24","doi-asserted-by":"publisher","first-page":"174480692211405","DOI":"10.1177\/17448069221140532","volume":"18","author":"M Wanying","year":"2025","unstructured":"Wanying M, Lulu M, Afang Z, Huan C, Yuguang H (2025) Astrocyte-microglia interaction through C3\/C3aR pathway modulates neuropathic pain in rats model of chronic constriction injury. Mol Pain 18:17448069221140532. https:\/\/doi.org\/10.1177\/17448069221140532","journal-title":"Mol Pain"},{"key":"2347_CR25","doi-asserted-by":"publisher","unstructured":"Koivisto H, Ytebrouck E, Carmans S, Naderi R, Miettinen P, Roucourt B et al (2019) Progressive age-dependent motor impairment in human tau P301S overexpressing mice. Behav Brain Res 376. https:\/\/doi.org\/10.1016\/j.bbr.2019.112158","DOI":"10.1016\/j.bbr.2019.112158"},{"issue":"17","key":"2347_CR26","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1073\/pnas.0913449107","volume":"107","author":"Y Chu","year":"2010","unstructured":"Chu Y, Jin X, Parada I, Pesic A, Stevens B, Barres B et al (2010) Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci USA 107(17):7975\u20137980. https:\/\/doi.org\/10.1073\/pnas.0913449107","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2347_CR27","doi-asserted-by":"publisher","first-page":"153089","DOI":"10.1016\/j.imbio.2025.153089","volume":"230","author":"WM Zelek","year":"2025","unstructured":"Zelek WM, Tenner AJ (2025) Complement therapeutics in neurodegenerative diseases. Immunobiology 230(4):153089. https:\/\/doi.org\/10.1016\/j.imbio.2025.153089","journal-title":"Immunobiology"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-026-02347-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02347-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-026-02347-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:16:12Z","timestamp":1787278572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40478-026-02347-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2347"],"URL":"https:\/\/doi.org\/10.1186\/s40478-026-02347-2","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received ethical approval from London Neurodegenerative disease brain bank (23\/WA\/0124).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"175"}}